BRIEF-Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms

Tenaya Therapeutics

Tenaya Therapeutics

TNYA

0.00

June 3 (Reuters) - Tenaya Therapeutics Inc TNYA.O:

  • TENAYA THERAPEUTICS ANNOUNCES INTERIM DATA FROM MYPEAK™-1 SHOWING TREATMENT OF MYBPC3-ASSOCIATED HCM WITH TN-201 GENE THERAPY RESULTED IN CONSISTENT SIGNS OF CARDIAC REMODELING AND REDUCTIONS IN SYMPTOMS

  • TENAYA THERAPEUTICS - ALL EVALUABLE PATIENTS SHOW IMPROVEMENTS IN MYBPC3-ASSOCIATED HCM AFTER TN-201 TREATMENT

  • TENAYA THERAPEUTICS - COHORT 1 BENEFITS SUSTAINED UP TO TWO YEARS; COHORT 2 SHOWS EARLIER IMPROVEMENT

  • TENAYA THERAPEUTICS - TN-201 WELL TOLERATED WITH NO NEW SAFETY EVENTS REPORTED

Source text: ID:nGNX7M2k8w

Further company coverage: TNYA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.